Superior drug penetration using the
Physion EMDA® system for the treatment of Non-Muscle Invasive Bladder Cancer and of Functional Urological Disorders
What is EMDA®
EMDA® is a device-assisted therapy that increases drug transport across biological membranes under the influence of an electric field
EMDA® is characterized by a combination of different electromolecular interactions that improves drug absorption from 4 to 7 times:
The deeper drug penetration and the greater drug bioavailability result in an increased clinical effectiveness
EAU Guidelines NMIBC 2021
220.127.116.11 Options to improving efficacy of intravesical chemotherapy
18.104.22.168.2 Device- assisted intravesical chemotherapy Electromotive Drug Administration
«The efficacy of MMC using EMDA® sequentially combined with BCG in patients with high-risk tumours has been demostrated in one small RCT (Di Stasi, 2006)» page 25
7.2.3 Combination therapy
22.214.171.124. Intravesical BCG + chemotherapy vs BCG alone
«In a RCT (Di Stasi, 2006) using MMC with EMDA®, a combination of BCG and MMC with EMDA® showed an improved recurrence-free interval and reduced progression rate compared to BCG monotherapy» page 28
7.4.3 Treatment of BCG unresponsive tumours and patients with BCG intolerance
«Currently, several bladder preservations strategies are being investigated such…device assisted instillations (Racioppi, 2018)» page 31
EMDA® versus Conventional Therapy
With EMDA® drug concentration is increased from 4 to 7 times
Is the active transport of ionised drug molecules into the target tissue by the application of an electric current through the intravesical solution
containing the ions to be delivered
Is the transport of non-ionized drug molecules associated with the transport of water
Implies increasing the permeability of biological membranes under the influence of an electric field
• BCG FAILURE
EMDA® field of application
A urogenic 16F electrode-catheter is inserted into the bladder
The bladder is drained to remove residual electrolytes
The drug solution is administered
Two dispersive electrodes are placed on the sides of the navel with an abundante layer of conductive gel
A micro-current is applied for 20 minutes
EMDA® treatment is quick, easy to use and safe
Clinical Benefits of EMDA®
Deeper drug penetration into the target tissue compared to conventional therapy
Significant reduction in disease recurrence and/or progression
Significant increase in disease-free interval
Emda® improves patients' quality of life
The applied electric current causes no biological damage to tissue and no chemical modification of drug
Drug plasma levels remain well below toxic levels
Excellent safety record
numerous clinical trials with long term follow-up have been conducted, focused on efficacy and safety of EMDA®
EMDA® FOR NON-MUSCLE INVASIVE BLADDER CANCER
The charts below compare the success and survival rates of patients treated with BCG only and BCG combined with EMDA® + Mitomycin
Sequential treatment BCG/EMDA® + Mitomycin
has an excellent oncologic efficacy and is twice as efficace as the traditional therapy
A unique technology to augment the effect of intravesical chemotherapy by creating an electric field across the bladder wall which increases urothelium’s permeability
EMDA® device-assisted drug delivery is a viable option to offer patients than radical cystectomy, particularly in BCG failure or intolerance or when other options are not viable
The Physion EMDA® system has been proved excellent results in treating high-risk and intermediate-risk patients with non-muscle invasive bladder cancer.
EMDA® + Mitomycin treatment is an efficacy tool in the long term conservative strategy of high-risk unresponsive to BCG as a “bladder sparing” therapy.
Several thousand treatment cycles have been performed with complete safety following TURBT: significantly reduced recurrence and progression with increased disease-free interval.
EMDA® can be used with all type of Mitomycin and in sequential treatment EMDA® + Mitomycin is combined with BCG.
More data on EMDA® now available than any other device assisted drug delivery system available.
Proven deeper tissue penetration of Mytomicin with EMDA® compared to passive administration.
In according to EAU Guidelines 2021.